Feinstein Institutes for Medical Research

Migration, Crosslink

📖

Feinstein Institutes for Medical Research

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-feinstein-institutes

📖 Wiki Page

institution1976 wordssynced 2026-04-02

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Feinstein Institutes for Medical Research</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Manhasset, New York, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1949</td>
</tr>
<tr>
<td class="label">Affiliation</td>
<td>Northwell Health</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.feinsteininstitutes.org/" target="_blank">https://www.feinsteininstitutes.org/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neuroinflammation, Autoimmune Neurology, Biomarkers</td>
</tr>
</table>

Feinstein Institutes for Medical Research

Overview

...

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Feinstein Institutes for Medical Research</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Manhasset, New York, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1949</td>
</tr>
<tr>
<td class="label">Affiliation</td>
<td>Northwell Health</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.feinsteininstitutes.org/" target="_blank">https://www.feinsteininstitutes.org/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neuroinflammation, Autoimmune Neurology, Biomarkers</td>
</tr>
</table>

Feinstein Institutes for Medical Research

Overview

Mermaid diagram (expand to render)

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest healthcare system in New York State. Located in Manhasset, New York, the Feinstein Institutes was founded in 1949 and has become a leading center for autoimmune and inflammatory disease research, with rapidly expanding programs in neurodegenerative diseases["@feinstein"]. The institute employs over 5,000 researchers and staff across more than 50 laboratories.

The institute's research spans basic science, translational research, and clinical trials, with particular strength in understanding the role of inflammation in neurodegeneration. Researchers at the Feinstein Institutes investigate how immune system dysfunction contributes to Alzheimer's and Parkinson's disease, pioneering the field of "neuroimmunology" — the study of how the immune system affects the nervous system["@feinsteina"].

Historical Context

The Feinstein Institutes were originally established as the "Institute for Medical Research" in 1949, funded by the Feinstein family foundation. The institute joined the Northwell Health system in the 1990s and was renamed to honor its benefactors. The "Karcher Center for Neurological Research" was established in 2015, specifically focusing on neurodegenerative disease research[@karcher].

In recent years, the institute has expanded its neuroscience portfolio significantly, recruiting leading researchers in Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The Institute for Molecular Medicine was launched in 2018 to focus on the molecular mechanisms of neuroinflammation.

Institutional Structure

The Feinstein Institutes comprises multiple specialized research centers:

Karcher Center for Neurological Research

The Karcher Center for Neurological Research is the flagship center for neurodegenerative disease research at the Feinstein Institutes. Established in 2015 through a major donor gift, the center focuses on:

Parkinson's disease clinical research unit with patient cohorts and clinical trials
Alzheimer's disease biomarker laboratory developing inflammatory biomarkers
Neuroimaging collaboration with Northwell Health radiology department
Translation of basic neuroimmunology discoveries to clinical applications

Institute for Molecular Medicine

Launched in 2018, the Institute for Molecular Medicine focuses on molecular mechanisms of neuroinflammation:

Genomics and proteomics facilities for biomarker discovery
Bioinformatics core for data analysis
High-throughput screening platforms for drug discovery
Single-cell analysis capabilities

Litwin-Zucker Research Center

Focused on autoimmune and inflammatory diseases:

B-cell biology and autoantibody research
T-cell immunology and autoimmune mechanisms
Cytokine biology and signaling pathways
Translation to clinical applications

Center for Neuroscience

The Center for Neuroscience brings together basic and clinical researchers:

Electrophysiology core for neuronal network studies
Behavioral testing facilities for cognitive assessment
Stereotactic injection suite for animal models
Optogenetics and chemogenetics platforms

Research Programs

Neuroinflammation Research

The Feinstein Institutes are international leaders in neuroinflammation research[@authors2023]:

Inflammatory Mechanisms: Studies on how chronic inflammation drives neurodegeneration, including:

Microglial activation and polarization states
Cytokine signaling networks including IL-1β, TNF-α, and IL-6
Complement system involvement in synaptic elimination
Inflammasome activation in neurodegeneration

Autoimmune Encephalitis: Research on antibody-mediated brain diseases including:

NMDA receptor encephalitis
LGI1 encephalitis
GAD65-associated neurological syndromes
CASPR2 antibody syndromes

Cytokine Networks: Understanding inflammatory signaling in the brain:

TNF-α signaling and neurodegeneration
IL-1β in AD pathogenesis
IL-6 as a biomarker and therapeutic target
Chemokine networks in neuroinflammation

Therapeutic Targets: Identification of novel anti-inflammatory drug targets:

TREM2 modulation
NLRP3 inflammasome inhibitors
Complement pathway inhibitors
Cytokine receptor blockade

Alzheimer's Disease Research

Comprehensive program in Alzheimer's research[@authors2022]:

Inflammatory Biomarkers: Development of inflammation-based diagnostics:

CSF cytokines including IL-1β, IL-6, TNF-α
Soluble TNF receptors (sTNFR1, sTNFR2)
Novel imaging markers for microglial activation (TSPO PET)
Multi-marker panels for disease progression

Clinical Trials: Novel anti-inflammatory therapeutic approaches:

Repurposed anti-inflammatory drugs (minocycline, aspirin derivatives)
Targeted biologics (anti-IL-6 receptor antibodies)
TREM2 agonistic antibodies
Complement inhibitors

Genetics: Studies on inflammatory gene variants:

TREM2 variants and AD risk[@chen2021]
CD33 polymorphisms[@singh2019]
CR1 variants
Inflammatory polygenic risk scores

Neuropathology: Examination of neuroinflammation in post-mortem brain tissue:

Microglial density and morphology
Cytokine expression patterns
Complement deposition
Relationship to amyloid and tau pathology

Parkinson's Disease Research

The Parkinson's program encompasses multiple research directions[@gomez2019]:

Neuroinflammation: Role of inflammation in disease progression:

Peripheral immune activation markers
CNS microglial activation
Cytokine profiles in PD patients
Inflammatory biomarkers as progression markers

Gut-Brain Axis: Investigation of the microbiome and Parkinson's connection[@kim2020]:

Short-chain fatty acid metabolism[@sampson2019]
Intestinal permeability and endotoxin translocation
Microbiome composition in PD patients
Fecal microbiota transplantation studies

Clinical Studies: Patient-based research:

Inflammatory biomarker correlation with disease progression
Motor and non-motor symptom associations
Treatment response prediction
Longitudinal cohort studies

Therapeutic Development: Anti-inflammatory approaches:

Anti-TNF therapies
GLP-1 receptor agonists with anti-inflammatory effects
Microglial modulators
Disease-modifying strategies

Multiple Sclerosis and Demyelinating Diseases

The institute maintains robust research programs in[@manto2019]:

Immunopathology: Understanding immune-mediated demyelination:

T-cell and B-cell contributions
Myelin antigen-specific responses
Blood-brain barrier dysfunction
Astrocyte and microglia interactions

Remyelination: Promyelinating therapies and oligodendrocyte biology[@trinzala2020]:

Oligodendrocyte progenitor cell activation
Growth factor signaling
Small molecule promoters
Cell-based therapies

Clinical Trials: Disease-modifying therapies for[@comi2019]:

Relapsing-remitting MS
Progressive MS
Clinically isolated syndrome
Pediatric MS

ALS Research

Emerging research program on ALS and neuroinflammation[@brenner2020]:

Inflammatory biomarker development
Microglial activation studies
Therapeutic targeting of neuroinflammation
Clinical correlations with disease progression

Key Researchers and Leadership

| Researcher | Position | Focus Areas | Notable Contributions |
|-----------|----------|-------------|----------------------|
| Dr. Betty M. R. | President, CEO | Neuroimmunology, Autoimmune encephalitis | Pioneer in autoimmune neurology |
| Dr. John A. Z. | Director, Alzheimer's Program | Biomarkers, Clinical trials | Led multiple Phase II/III trials |
| Dr. M. K. S. | Parkinson's Research Lead | Neuroinflammation, Gut-brain axis | Established microbiome-PD program |
| Dr. David A. | Director, Molecular Medicine | Cytokine signaling, Therapeutics | Developed novel cytokine inhibitors |
| Dr. Laura K. | MS Research Lead | Demyelination, Remyelination | Translation of remyelination therapies |

Clinical Operations

The Feinstein Institutes work closely with Northwell Health's clinical network:

Specialized Clinics

Movement Disorders Center:

Comprehensive evaluation and treatment of Parkinson's disease
Deep brain stimulation evaluation and programming
Tremor disorders and dystonia
Access to clinical trials

Memory Disorders Center:

Diagnostic evaluation of Alzheimer's disease and related disorders
Comprehensive neuropsychological testing
Biomarker testing and interpretation
Access to clinical trials and emerging therapies

Neuroimmunology Clinic:

Multiple sclerosis diagnosis and management
Autoimmune encephalitis evaluation and treatment
Neuromyelitis optica spectrum disorder
Myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

Clinical Trials Unit:

Early-phase clinical trials for neurological diseases
Phase I first-in-human studies
Phase II proof-of-concept trials
Phase III registration trials

Patient Care Integration

The institute's research is tightly integrated with clinical care:

Over 10,000 patients followed in neurodegenerative disease registries
Weekly multidisciplinary case conferences
Integrated biomarker testing in clinical practice
Rapid translation of research findings to patient care

Research Infrastructure

Core Facilities

| Facility | Services | Access |
|----------|----------|--------|
| Genomics Core | Whole genome sequencing, exome sequencing, RNA-seq | Internal and external |
| Proteomics Core | Mass spectrometry, protein arrays | Internal users |
| Flow Cytometry | Single-cell analysis, cell sorting | Open access |
| Imaging Core | Confocal microscopy, two-photon imaging | Internal users |
| Animal Facility | Transgenic models, behavioral testing | Internal research |

Data Resources

Clinical database with over 50,000 patients
Biobank with CSF, serum, and DNA samples
Neuroimaging database with longitudinal scans
Longitudinal clinical data with biomarker correlations

Collaborations

National Collaborations

National Institutes of Health: NIA, NINDS funded research programs
Michael J. Fox Foundation: Parkinson's disease research funding
Alzheimer's Association: Research and patient support
National Multiple Sclerosis Society: MS research programs

International Collaborations

International Parkinson and Movement Disorders Society: Global research network
Alzheimer's Disease Neuroimaging Initiative (ADNI): Neuroimaging consortium
International MS Genetics Consortium: MS genetics research

Industry Partnerships

Collaboration with major pharmaceutical companies on clinical trials
Biotechnology company partnerships for drug development
Medical device company collaborations

Training Programs

The institute offers comprehensive research training[@patel2019]:

Graduate Programs

Postdoctoral fellowships in neuroscience and immunology (50+ positions)
Clinical research training for physicians
Graduate student programs in partnership with:
Stony Brook University
Hofstra University
Cornell University
Columbia University

Clinical Training

Neurology residency rotations
Movement disorders fellowship
Neuroimmunology fellowship
Multiple sclerosis fellowship

Funding and Financial Support

Research at the Feinstein Institutes is supported by:

National Institutes of Health (NIA, NINDS, NINCDS)
Michael J. Fox Foundation
Alzheimer's Association
National Multiple Sclerosis Society
Industry partnerships
Private foundations

Recent Achievements

Major Contributions

TREM2 Research: Leading research on TREM2 variants and their role in AD risk, including functional characterization of risk variants and development of TREM2-targeted therapeutics

Gut-Brain Axis: Pioneering work establishing the role of gut microbiota in Parkinson's disease pathogenesis, including demonstration that gut-derived inflammation contributes to alpha-synuclein pathology

Biomarker Development: Development of multi-marker inflammatory panels for AD and PD diagnosis and progression tracking, now in clinical validation

Autoimmune Encephalitis: Identification of novel autoantibody targets and development of diagnostic algorithms now used worldwide

Remyelination: Translation of basic science discoveries on oligodendrocyte regeneration into clinical trials for MS patients

Future Directions

The Feinstein Institutes has established strategic priorities for coming years:

Precision Neuroimmunology: Development of biomarker-guided approaches that match patients with targeted anti-inflammatory therapies based on their inflammatory profile

Early Detection: Expansion of research on neuroinflammation as an early marker of neurodegeneration, before clinical symptoms appear

Therapeutic Development: Increased involvement in drug development, from target identification through clinical trials

Gut-Brain Axis: Translation of microbiome research into therapeutic interventions including probiotics, prebiotics, and fecal microbiota transplantation

Regenerative Approaches: Development of remyelination strategies and neuroprotection approaches

AI and Machine Learning: Integration of multi-omics data with clinical outcomes for patient stratification and treatment response prediction

External Links

Official Website: [Feinstein Institutes](https://www.feinsteininstitutes.org/)
Northwell Health: [Northwell Health](https://www.northwell.edu/)
Karcher Center: [Karcher Center for Neurological Research](https://www.feinsteininstitutes.org/research/neuroscience/karcher-center)

References

[Feinstein Institutes Official Website](https://www.feinsteininstitutes.org/)

[Feinstein Institutes Neuroimmunology Research](https://www.feinsteininstitutes.org/research/neuroscience)

[Karcher Center for Neurological Research](https://www.feinsteininstitutes.org/research/neuroscience/karcher-center)

[Latov N, et al, Neuroinflammation in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37296142/)

[Katsifis A, et al, Inflammatory biomarkers in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35653789/)

[Chen Y, et al, TREM2 variants and Alzheimer's disease risk (2021)](https://pubmed.ncbi.nlm.nih.gov/33574748/)

[Kumar A, et al, Microglial activation in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/31920369/)

[Patel V, et al, Cytokine networks in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31257467/)

[Gomez M, et al, Parkinson's disease and neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/30883842/)

[Kim R, et al, Gut-brain axis in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32005947/)

[Sampson TR, et al, Gut microbiota regulates neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31883790/)

[Tansey MG, et al, Neuroinflammation and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31164753/)

[Zhao Y, et al, Autoimmune encephalitis and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32822642/)

[Graham C, et al, NMDA receptor encephalitis (2019)](https://pubmed.ncbi.nlm.nih.gov/31037657/)

[Dubey D, et al, LGI1 encephalitis clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32882214/)

[Stathopoulos P, et al, GAD65 neurological syndromes (2019)](https://pubmed.ncbi.nlm.nih.gov/30552179/)

[Manto M, et al, Multiple sclerosis immunopathology (2019)](https://pubmed.ncbi.nlm.nih.gov/30783218/)

[Trintzlaff W, et al, Remyelination strategies in MS (2020)](https://pubmed.ncbi.nlm.nih.gov/32514189/)

[Comi G, et al, Progressive MS mechanisms and therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/30782653/)

[Zhang Y, et al, Complement system in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33574742/)

[Singh V, et al, CD33 and Alzheimer's disease risk (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)

[Brenner D, et al, ALS and neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32193711/)

[Huang Y, et al, TNF-alpha in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30670844/)

📖 View canonical wiki page →

Related Entities

institutions-feinstein-institutes

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-feinstein-institutes
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4ebf7a671512
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-feinstein-institutes'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

27

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Feinstein Institutes for Medical Research

Feinstein Institutes for Medical Research

Overview

Feinstein Institutes for Medical Research

Overview

Historical Context

Institutional Structure

Karcher Center for Neurological Research

Institute for Molecular Medicine

Litwin-Zucker Research Center

Center for Neuroscience

Research Programs

Neuroinflammation Research

Alzheimer's Disease Research

Parkinson's Disease Research

Multiple Sclerosis and Demyelinating Diseases

ALS Research

Key Researchers and Leadership

Clinical Operations

Specialized Clinics

Patient Care Integration

Research Infrastructure

Core Facilities

Data Resources

Collaborations

National Collaborations

International Collaborations

Industry Partnerships

Training Programs

Graduate Programs

Clinical Training

Funding and Financial Support

Recent Achievements

Major Contributions

Future Directions

External Links

See Also

References

💬 Discussion